Overview

Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants

Status:
Active, not recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the humoral immune responses to Takeda's Tetravalent Dengue Vaccine Candidate (TDV) administered subcutaneously in a subset of healthy participants between 2 and <18 years of age living in dengue endemic countries.

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

Vaccines